Related references
Note: Only part of the references are listed.In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
Yiqun Li et al.
FRONTIERS IN ONCOLOGY (2022)
Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
G. R. Hancock et al.
NPJ BREAST CANCER (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER plus Breast Cancer
Jun Liang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer
Youssef El-Ahmad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening
Jian Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER plus Breast Cancer
Jun Liang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist
James S. Scott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha
Birong Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design
Ercheng Wang et al.
CHEMICAL REVIEWS (2019)
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
Mehmet Kahraman et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Acquired resistance to aromatase inhibitors: where we stand!
Tiago Vieira Augusto et al.
ENDOCRINE-RELATED CANCER (2018)
Computational Alanine Scanning with Interaction Entropy for Protein-Ligand Binding Free Energies
Xiao Liu et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2018)
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer
George S. Tria et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Recent Advances in the Treatment of Breast Cancer
Christy W. S. Tong et al.
FRONTIERS IN ONCOLOGY (2018)
A Computational Investigation of Small-Molecule Engagement of Hot Spots at Protein-Protein Interaction Interfaces
David Xu et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2017)
Molecular Simulation Studies on the Binding Selectivity of Type -I Inhibitors in the Complexes with ROS1 versus ALK
Yuanxin Tian et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2017)
Optimizing Quality of Life in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: Treatment Options and Considerations
Pavani Chalasani
ONCOLOGY (2017)
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
Hazel M. Weir et al.
CANCER RESEARCH (2016)
Twenty years on: the impact of fragments on drug discovery
Daniel A. Erlanson et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER plus breast cancer
James D. Joseph et al.
ELIFE (2016)
The changing role of ER in endocrine resistance
Agostina Nardone et al.
BREAST (2015)
Evolutions in fragment-based drug design: the deconstruction-reconstruction approach
Haijun Chen et al.
DRUG DISCOVERY TODAY (2015)
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
Chris De Savi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
Michel van Kruchten et al.
CANCER DISCOVERY (2015)
Setting the Record Straight: The Origin of the Pharmacophore Concept
Osman F. Guener et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
Fragment-Based Lead Discovery and Design
Diane Joseph-McCarthy et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
The role of ligand efficiency metrics in drug discovery
Andrew L. Hopkins et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
The development of endocrine therapy for women with breast cancer
Richard Sainsbury
CANCER TREATMENT REVIEWS (2013)
Molecular Pathology of Breast Cancer What a Pathologist Needs to Know
Kimberly H. Allison
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Tamoxifen Resistance in Breast Cancer
Minsun Chang
BIOMOLECULES & THERAPEUTICS (2012)
Fragment Based Drug Design: From Experimental to Computational Approaches
A. Kumar et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking
Michael M. Mysinger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Strategies for the discovery and development of therapies for metastatic breast cancer
Bedrich L. Eckhardt et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery
Roman A. Laskowski et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer
Donald P. McDonnell et al.
CURRENT OPINION IN PHARMACOLOGY (2010)
Principles of protein-protein interactions: What are the preferred ways for proteins to interact?
Ozlem Keskin et al.
CHEMICAL REVIEWS (2008)
Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer
O. E. Young et al.
EUROPEAN JOURNAL OF CANCER (2008)
Metabolic activation of carboxylic acids
Christian Skonberg et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Hot-spots-guided receptor-based pharmacophores (HS-Pharm): A knowledge-based approach to identify ligand-anchoring atoms in protein cavities and prioritize structure-based pharmacophores
Caterina Barillari et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2008)
Characterization of molecular and structural determinants of selective estrogen receptor downregulators
Meiyun Fan et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Evaluating virtual screening methods: Good and bad metrics for the early recognition problem
Jean-Francois Truchon et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2007)
Predicting protein interaction sites: binding hot-spots in protein-protein and protein-ligand interfaces
Nicholas J. Burgoyne et al.
BIOINFORMATICS (2006)
A comprehensive listing of bioactivation pathways of organic functional groups
AS Kalgutkar et al.
CURRENT DRUG METABOLISM (2005)
Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy
RA Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening
TA Halgren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Aromatase inhibitors in the treatment and prevention of breast cancer
PE Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Aromatase inhibitors and their application in breast cancer treatment
AMH Brodie et al.
STEROIDS (2000)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
